US Dollar vs MXN

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

VRTX Vertex Pharmaceuticals Inc

405.76

3.06 (0.76%)

Fuera de horario

Última actualización: 17:08:44

Retrasado por 15 minutos

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/15/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/08/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for David Altshuler

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Vertex Pharmaceuticals (NASDAQ:VRTX)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025

Haga Click aquí para más Gráficas Vertex Pharmaceuticals.

Vertex Pharmaceuticals (NASDAQ:VRTX)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025

Haga Click aquí para más Gráficas Vertex Pharmaceuticals.

Noticias sobre Vertex Pharmaceuticals Inc VRTX

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
Lunes 23 de Diciembre 2024 (1 semana hace) • Business Wire

Form 8-K - Current report
Viernes 20 de Diciembre 2024 (2 semanas hace) • Edgar (US Regulatory)

Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Viernes 20 de Diciembre 2024 (2 semanas hace) • Business Wire

Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants
Viernes 20 de Diciembre 2024 (2 semanas hace) • Business Wire

Vertex Announces Results From Phase 2 Study of Suzetrigine for the Treatment of Painful Lumbosacral Radiculopathy
Jueves 19 de Diciembre 2024 (2 semanas hace) • Business Wire

Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the American Society of Hematology (ASH) Annual Meeting and Exposition and Provides Program Update
Domingo 8 de Diciembre 2024 (4 semanas hace) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Martes 19 de Noviembre 2024 (1 mes hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 15 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Miércoles 13 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Martes 12 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Viernes 8 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Martes 5 de Noviembre 2024 (2 meses hace) • Edgar (US Regulatory)

Más de Vertex Pharmaceuticals Inc Artículos de Noticias

Invesco QQQ Trust Series 1

Deutsche Telekom (QX)

American Express

Gold vs US Dollar

Bank of America

Delayed Upgrade Clock

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones